7.41
price up icon3.49%   0.25
after-market Handel nachbörslich: 7.41
loading

Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten

pulisher
Jul 15, 2025

What makes USCB stock price move sharplyFree Stock Market Query - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes AerCap Holdings N.V. stock price move sharplyFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Gyre Therapeutics Inc. stock price move sharplyLong Term Secure Gain Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Gyre Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes ABCL stock price move sharplyInstant Stock Updates - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Gyre Therapeutics Inc. stock performs during market volatilityInstant Stock Updates - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How High Can LDO(lidodaotoken) GoFree VIP Group - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Head to Head Analysis: Gyre Therapeutics (NASDAQ:GYRE) versus Entera Bio (NASDAQ:ENTX) - Defense World

Jul 09, 2025
pulisher
Jun 30, 2025

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 13, 2025

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN

Jun 13, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics (GYRE) Begins Phase 1 Trial for Pulmonary Hypertension Drug | GYRE Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - TradingView

Jun 10, 2025
pulisher
Jun 10, 2025

Novel PAH Drug Enters Clinical Trials in $370M China Market, Targeting Rare Disease with High Mortality - Stock Titan

Jun 10, 2025
pulisher
Jun 06, 2025

Gyre Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 06, 2025
pulisher
May 29, 2025

Gyre Therapeutics Closes $23 Million Public Offering - MarketScreener

May 29, 2025
pulisher
May 29, 2025

Gyre Therapeutics Raises $23M in Public Offering for MASH Clinical Trials | GYRE Stock News - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 29, 2025
pulisher
May 29, 2025

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Globe and Mail

May 29, 2025
pulisher
May 27, 2025

What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq

May 27, 2025
pulisher
May 27, 2025

MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga

May 27, 2025
pulisher
May 26, 2025

GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com

May 26, 2025
pulisher
May 25, 2025

Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN

May 25, 2025
pulisher
May 25, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World

May 25, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Announces Stock Offering Agreement - TipRanks

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering - Investing.com

May 23, 2025
pulisher
May 23, 2025

GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics commences underwritten public offering - MSN

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock - The Manila Times

May 23, 2025
pulisher
May 23, 2025

GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics tumbles after stock offering launch - TradingView

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan

May 22, 2025
pulisher
May 15, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Gyre Therapeutics Reports Q1 2025 Financial Results - MSN

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 14, 2025
pulisher
May 13, 2025

GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq

May 13, 2025
$21.87
price up icon 3.40%
$35.60
price down icon 2.49%
$104.59
price up icon 1.67%
$28.27
price up icon 16.05%
$112.49
price up icon 1.66%
biotechnology ONC
$279.16
price up icon 3.51%
Kapitalisierung:     |  Volumen (24h):